Moreover, as activation of the CXCL12/CXCR4 axis stimulates VEGF and MMP production in mature endothelial cells (138), CXCR4 antagonists also inhibit tumor angiogenesis in animal models of human tumors (68). This evidence concerns the gene VEGFA and neoplasm.